Amide Compounds for CNS Distribution in Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting neurodegenerative diseases face challenges in achieving effective distribution to the central nervous system (CNS), particularly for conditions like myelination defects, where thyroid hormone signaling pathways offer potential but existing compounds like T4 and T3 have adverse effects.
Innovation Solution
Development of specific amide compounds, such as those described in Formulas I, II, III, and IV, which are designed to improve CNS distribution and minimize peripheral tissue activity, potentially activating thyroid hormone pathways without adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional thyroid hormones T4 and T3 are used as therapeutics, then thyroid hormone signaling pathways are activated, but adverse effects such as tachycardia, muscle wasting, and osteoporosis occur due to lack of therapeutic index
Solution Approach 1:
The patent applies local quality by designing compounds that exhibit tissue-selective thyroid hormone action, specifically targeting the brain while sparing peripheral tissues. The compounds of Formula I are engineered to activate thyroid hormone signaling pathways preferentially in the central nervous system, achieving local therapeutic effects without systemic adverse effects on heart, muscle, or bone.
Solution Approach 2:
The patent uses sobetirome (GC-1) as an intermediary compound that mediates thyroid hormone signaling in a tissue-selective manner. Sobetirome serves as a synthetic T3 agonist that activates thyroid hormone pathways in the brain while avoiding the adverse effects of traditional T4 and T3, acting as a bridge between the need for thyroid hormone activity and the avoidance of hyperthyroidism-related side effects.
2Object-affected harmful factors
If sobetirome is used to activate thyroid hormone pathways selectively, then peripheral tissue adverse effects are minimized, but CNS distribution efficiency is insufficient for optimal treatment of neurodegenerative diseases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sobetirome through the introduction of various amide substituents (R1-R4 groups in Formula I). These structural modifications alter the pharmacokinetic parameters of the compound, specifically improving its ability to cross the blood-brain barrier and enhance CNS distribution while maintaining tissue-selective activity and minimizing peripheral effects.
3Quantity of substance
If compounds are designed to improve CNS penetration, then brain-to-serum ratios increase, but peripheral tissue activity may be reduced
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic effect into two distinct components: CNS-specific activity and peripheral tissue activity. The compounds of Formula I are designed to segment their pharmacological action, with primary activation of thyroid hormone pathways in the brain while maintaining minimal or selective activity in peripheral tissues, allowing independent optimization of each compartment's therapeutic response.
Data Source
AI summary
Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.